Currently, c-MET inhibitors are mainly used in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), papillary renal cell carcinoma (PRCC), gastric cancer (GC), breast cancer (BC), hepatocellular carcinoma, melanoma, and glioblastoma multiforme (GBM), all of which have a high frequency of MET-related mutations (especially the exon 14 skipping alterations (METex14) and amplification) [90–93]. This evidence concerns the gene MET and glioblastoma.